Skip to main content

Table 1 Comparisons of sex, age, H. pylori infection, and mutations of the 23S rRNA gene between subjects with and without CLR use history

From: Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history

Groups

 

Placebo

OA

OAC

(Total)

CLR use history

 

-

-

+

 

Case No.

 

310

307

153

770

Sex ratio (M:F)

 

1:1.00

1:1.13

1:0.82

1:1.01

Age (yrs) (Mean ± SD)

 

45.3 ± 8.4

45.0 ± 8.4

45.7 ± 8.6

45.2 ± 8.5

H. pylori-positive rate in 2003 (%)

13C-UBT

90.6 (280/309)

54.11 (166/307)

53.3 (81/152)

68.1 (527/768)

 

ELISA

92.5 (283/306)

62.11 (185/298)

44.12 (64/145)

71.0 (532/749)

 

23S rRNA

83.9 (260/310)

51.11 (157/307)

26.82 (41/153)

59.5 (458/770)

Proportion of 2143G-positive H. pylori (%)

Total CLRr

13.8 (36/260)

10.2 (16/157)

31.73 (13/41)

14.2 (65/458)

 

CLRr & s

9.6 (25/260)

6.4 (10/157)

14.6 (6/41)

9.0 (41/458)

Proportion of MboII-RFLP-positive H. pylori (%)

2222CTTCA

0.4 (1/260)

1.9 (3/157)

4.94 (2/41)

1.3 (6/458)

 

2081GAAG

1.9 (5/260)

1.3 (2/157)

14.65 (4/41)

2.4 (11/458)

  1. 1: OA group vs. placebo group, p < 0.0000;
  2. 2: OAC group vs. OA group, p < 0.0005;
  3. 3: OAC group vs. OA group, OR = 4.09, 95%CI [1.64–10.23]; OAC group vs. placebo group, OR = 2.89, 95%CI [1.28–6.46];
  4. 4: OAC group vs. OA group, OR = 2.63, 95%CI [0.30–20.29]; OAC group vs. placebo group, OR = 13.28, 95%CI [0.91–379];
  5. 5: OAC group vs. OA group, OR = 8.38, 95%CI [1.25–68.84]; OAC group vs. placebo group, OR = 5.51, 95%CI [1.18–25.12]